SHORT MINI-FUTURE - GENMAB | Delayed Deutsche Boerse AG 11:12:18 28/06/2024 pm IST | ||
| 23.59 EUR | +2.65% |
|
| Current month | +12.23% | ||
| 1 month | +11.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 23.59 | +2.65% |
| 27/24/27 | 22.98 | +0.13% |
| 26/24/26 | 22.95 | -0.26% |
| 25/24/25 | 23.01 | +0.17% |
| 24/24/24 | 22.97 | +0.17% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 11:12 pm IST
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VQ9JYE |
| ISIN | DE000VQ9JYE8 |
| Date issued | 13/07/2021 |
| Strike | 3,514 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 14.22 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 23.8 € |
|---|---|
| Lowest since issue | 2.95 € |
| Spread | 0.72 € |
| Spread % | 3.02% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,745
DKK
Average target price
2,464
DKK
Spread / Average Target
+41.20%
- Stock Market
- Certificates
- Certificat
